Seongnam-si, South Korea

Kyung Ah Kim

USPTO Granted Patents = 24 


Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Hwaseong-Si, KR (2011)
  • Seoul, KR (2016)
  • Seongnam-si, KR (2015 - 2020)

Company Filing History:


Years Active: 2011-2020

Loading Chart...
Loading Chart...
24 patents (USPTO):Explore Patents

Title: Kyung Ah Kim: Innovator in Dual-Targeting Cancer Therapies

Introduction

Kyung Ah Kim, based in Seongnam-si, South Korea, is a prolific inventor with a remarkable portfolio of 24 patents. His innovative work primarily focuses on advancements in cancer treatment, particularly through the development of biomarkers and dual-targeting agents.

Latest Patents

Among his latest groundbreaking patents, Kyung Ah Kim has developed a biomarker known as PNCK, which is pivotal for predicting the effect of a dual-targeting agent aimed at both c-Met and EGFR. This patent provides a method for predicting the effectiveness of the dual-targeting agent, as well as for selecting suitable subjects for its application and monitoring the agent's effects through the measurement of PNCK levels or its coding gene. Additionally, he has patented a method for predicting and monitoring the efficacy of a c-Met inhibitor by utilizing mutations in KRAS or BRAF, offering a pathway for selecting appropriate subjects for treatment and potentially ameliorating cancer through targeted therapy.

Career Highlights

Kyung Ah Kim has contributed significantly to his field during his tenure at renowned companies such as Samsung Electronics Co., Ltd. and the Samsung Life Welfare Foundation. His work has been instrumental in pushing the boundaries of cancer treatment and therapy development.

Collaborations

Throughout his career, he has collaborated with notable colleagues like Ji Min Lee and Bo Gyou Kim. These partnerships have fostered an environment of innovation, resulting in the successful development of transformative cancer therapies.

Conclusion

Kyung Ah Kim's contributions to the field of oncology through his inventions and patents exemplify his dedication to improving cancer treatment. His innovative use of biomarkers and dual-targeting agents marks a significant advancement in personalized medicine, showcasing his role as a leading inventor in this crucial area of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…